Misophonia: Independent Evidence on Diagnosis, CBT & Who Funds It
Misophonia is common and can be disabling. Group CBT has the best trial support, but evidence is thin, no medicine is licensed, and one philanthropy funds much of the field.
Independent research on stress, anxiety and depression — supplement and lifestyle claims graded honestly, with funding and conflicts made transparent.
Misophonia is common and can be disabling. Group CBT has the best trial support, but evidence is thin, no medicine is licensed, and one philanthropy funds much of the field.
Cyclothymia is a long-lasting, milder bipolar-spectrum mood condition. One therapy trial is promising, but no medicine has been properly tested for it.
Probiotics may slightly help depression as an add-on to antidepressants, but not alone. We trace the strain-specific trials, the industry money and the safety risks.
N-acetylcysteine helped adult hair-pulling and skin-picking in single trials, but larger trials in OCD, depression, bipolar and cannabis use were mostly negative.
L-methylfolate (Deplin) may add a small benefit to an antidepressant, but the key positive trial was industry-linked, folic acid failed a large UK trial, and MTHFR testing is not recommended.
CBD calmed nerves in small one-off public-speaking tests, but trials in diagnosed anxiety are few and mixed, and an FDA trial found liver-enzyme rises at consumer-range doses.
Adding aripiprazole, quetiapine or other antipsychotics to an antidepressant helps modestly, with frequent akathisia, weight gain and metabolic risks.
Ketamine infusions ease treatment-resistant depression fast, but the effect fades, long-term data are thin, and at-home products carry an FDA warning.
Prazosin helped PTSD nightmares in small trials, but the largest VA trial was negative. We weigh the evidence, blood pressure risks and who paid.
Zuranolone eases severe postpartum depression modestly faster than placebo in company-run trials, but long-term benefit is unproven and it carries a driving and sedation warning.
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.